Aromatase Inhibitor
Information
- Drug Name
- Aromatase Inhibitor
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| estrogen-receptor positive breast cancer |
ESR1 p.Ser463Pro (p.S463P) ( ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5, ENST00000456483.3 ) ESR1 p.Ser463Pro (p.S463P) ( ENST00000456483.3, ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5 ) |
D |
Predictive
|
Supports
|
Resistance | Somatic | 2 | 24185512 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| ESR1 S463P variants were observed after extensive ... | ESR1 |
ESR1 p.Ser463Pro (p.S463P) ( ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5, ENST00000456483.3 ) ESR1 p.Ser463Pro (p.S463P) ( ENST00000456483.3, ENST00000206249.8, ENST00000338799.9, ENST00000406599.5, ENST00000427531.6, ENST00000440973.5, ENST00000443427.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02767661 | Active, not recruiting | Phase 3 | Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer | July 19, 2017 | May 2024 |
| NCT03959891 | Active, not recruiting | Phase 1 | AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | May 30, 2019 | December 2024 |
| NCT00766532 | Completed | Phase 4 | Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? | January 2009 | October 2010 |
| NCT01160211 | Completed | Phase 3 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | May 5, 2011 | June 6, 2022 |
| NCT06086340 | Completed | Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. | September 29, 2023 | January 24, 2024 | |
| NCT01248416 | Completed | Phase 3 | Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature | November 2010 | September 2016 |
| NCT01446159 | Completed | Phase 2 | Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer | June 13, 2011 | June 28, 2019 |
| NCT01491737 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | February 17, 2012 | November 14, 2019 |
| NCT01654185 | Completed | Phase 2 | Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer | July 2012 | July 2016 |
| NCT05361655 | Completed | Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor | September 1, 2021 | September 1, 2021 | |
| NCT02040857 | Completed | Phase 2 | Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | January 2014 | May 2020 |
| NCT05043506 | Completed | European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies | February 8, 2022 | November 2, 2023 | |
| NCT03477396 | Completed | Phase 2 | Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer | June 14, 2018 | June 5, 2023 |
| NCT05012644 | Completed | Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone | February 17, 2021 | December 9, 2021 | |
| NCT04507022 | Completed | Phase 4 | The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer | August 12, 2020 | February 5, 2021 |
| NCT00773695 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer | November 7, 2008 | November 9, 2022 |
| NCT06440967 | Not yet recruiting | Phase 3 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | June 30, 2024 | August 31, 2027 |
| NCT05801705 | Not yet recruiting | Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | June 1, 2023 | December 30, 2023 | |
| NCT06107673 | Recruiting | Phase 2 | Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | September 30, 2023 | December 1, 2025 |
| NCT04762979 | Recruiting | Phase 2 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | February 12, 2021 | January 2025 |
| NCT06218303 | Recruiting | Phase 1 | Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | February 7, 2024 | August 31, 2028 |
| NCT05700006 | Recruiting | Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging | July 25, 2022 | July 2026 | |
| NCT01220128 | Terminated | Phase 2 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | April 11, 2011 | November 14, 2014 |
| NCT03910712 | Unknown status | Phase 2 | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC | June 1, 2019 | December 1, 2023 |
| NCT02910050 | Unknown status | Phase 2 | Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | January 2016 | December 2018 |
| NCT00935558 | Withdrawn | Phase 2 | Dendritic Cell Based Therapy for Breast Cancer Patients | July 2009 | |
| NCT01814865 | Withdrawn | Phase 2 | Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer | May 2013 | December 2013 |
| NCT03846583 | Withdrawn | Phase 1 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | June 28, 2020 | September 22, 2020 |